Phio presents data that underscores INTASYL's significance in immune cell-mediated cancer cell destruction

2 min read | October 07, 2024 06:20 AM PDT | By Team Kalkine Media

Google News:

Phio presents data that underscores INTASYL's significance in immune cell-mediated cancer cell destruction — Image source: Shutterstock

Recent News

Oracle's AI Push Gains Ground Across Critical Services

Why is Marathon Petroleum (NYSE:MPC) moving with S&P 500 Energy?

Why AbbVie (NYSE:ABBV) Gains in S&P 500 Index Biopharma Push?

Why FactSet Research Systems Anchors Index Stability Gains Now?

Make Kalkine Media
My Trusted Source

Highlights:

Phio Pharmaceuticals Corp. has unveiled data from its proprietary INTASYL platform, which effectively silences mRNA to enhance immune responses against cancer.
Key INTASYL compounds include PH-762, PH-894, PH-804, and PH-905, each targeting different pathways to improve therapeutic efficacy and immune cell activity.
The data will be presented at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal on October 8th.

Phio Pharmaceuticals Corp. {NASDAQ:PHIO} has announced significant advancements in its proprietary INTASYL platform, which showcases a novel approach to silencing mRNA both intracellularly and extracellularly. This innovative technology enhances immune responses against cancer and is applicable in various therapeutic settings, including intratumoral injections and immune cell expansion for adoptive cell therapy. Notably, the INTASYL platform requires no specialized formulations for small interfering RNA (siRNA) delivery, streamlining its use in clinical applications.

Among the key compounds developed under the INTASYL platform are:

PH-762: This compound targets PD-1, a checkpoint inhibitor, and has been shown to improve therapeutic efficacy in vivo, potentially increasing the effectiveness of cancer treatments.
PH-894: This compound silences BRD4, which enhances tumor cell immunogenicity and induces apoptosis, thereby promoting the body’s immune response against tumors.
PH-804: Designed to silence TIGIT in natural killer (NK) cells, PH-804 enhances cell activation, cytokine release, and target cell killing, further empowering the immune system's ability to fight cancer.
PH-905: This compound silences CBLB, which increases NK cell cytotoxicity and proliferation, contributing to a more robust immune attack on tumor cells.

Phio Pharmaceuticals plans to present this groundbreaking data at the upcoming 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal on October 8th, highlighting the potential of the INTASYL platform to revolutionize cancer immunotherapy and improve patient outcomes.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.